Literature DB >> 12465997

Current trachoma treatment methodologies: focus on advancements in drug therapy.

Loretta M Chiu1, Guy W Amsden.   

Abstract

Currently, there are approximately 6 million people with irreversible blindness as a result of chronic follicular conjunctivitis with subsequent corneal scarring caused by Chlamydia trachomatis, also known as trachoma. On the basis of the clinical studies evaluated, the most widely tested effective pharmacological treatments for trachoma today are topical tetracycline 1% to be applied to both eyes twice daily for 6 weeks or a single oral dose of azithromycin 20 mg/kg (up to 1g). Although chemotherapy can generate prompt therapeutic response and surgery can reverse the repercussions of these infections, these conditions will persist through reinfections. Implementing proper personal hygiene and environmental improvement measures for the control of infection transmission will be essential in reducing the potentially devastating results of trachoma infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12465997     DOI: 10.2165/00003495-200262180-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  26 in total

1.  Can we eliminate trachoma?

Authors:  T Lietman; A Fry
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Trachoma.

Authors:  D Mabey; N Fraser-Hurt
Journal:  BMJ       Date:  2001-07-28

3.  A trachoma perspective.

Authors:  H R Taylor
Journal:  Ophthalmic Epidemiol       Date:  2001-07       Impact factor: 1.648

Review 4.  The SAFE strategy for trachoma control: planning a cost-effectiveness analysis of the antibiotic component and beyond.

Authors:  K D Frick; S K West
Journal:  Ophthalmic Epidemiol       Date:  2001-09       Impact factor: 1.648

5.  Operational comparison of single-dose azithromycin and topical tetracycline for trachoma.

Authors:  R J Bowman; A Sillah; C Van Dehn; V M Goode; M M Muqit; M Muquit; G J Johnson; P Milligan; J Rowley; H Faal; R L Bailey
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

6.  Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.

Authors:  G W Amsden; A N Nafziger; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 7.  Azithromycin: indications for the future?

Authors:  J M Duran; G W Amsden
Journal:  Expert Opin Pharmacother       Date:  2000-03       Impact factor: 3.889

Review 8.  Trachoma.

Authors:  H R Taylor
Journal:  Int Ophthalmol       Date:  1990-05       Impact factor: 2.031

Review 9.  The SAFE strategy for the elimination of trachoma by 2020: will it work?

Authors:  R Bailey; T Lietman
Journal:  Bull World Health Organ       Date:  2003-07-07       Impact factor: 9.408

10.  Strategies for treatment and control of blinding trachoma: cost-effectiveness of topical or systemic antibiotics.

Authors:  C R Dawson; J Schachter
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.